Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by angelbanua1on Dec 01, 2020 10:07am

496 Views

Post# 32008707

Blood Stream

This might keep you updated. Try it out now!

It is said that this revolutionary inhaler device delivers measured amounts of green leaf directly into the systemic blood stream through the lungs, and with a short burst of aerosolized medicine. It is also approx 98% bioavailable, with only around 2% lost during exhalation.

Felt great that I found this! Check Disclaimer on my Profile

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"